Adverse Event Management of CAR-T in R/R MM

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of hematologic malignancies.